Cover Image
Market Research Report
Product code
908478

Multiplex Assays

Published: | Global Industry Analysts, Inc. | 375 Pages | Delivery time: 1-2 business days

Price

Back to Top
Multiplex Assays
Published: April 1, 2021
Global Industry Analysts, Inc.
Content info: 375 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Abstract:

Global Multiplex Assays Market to Reach $4 Billion by 2027

Amid the COVID-19 crisis, the global market for Multiplex Assays estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at a CAGR of 6.3% over the analysis period 2020-2027. Consumables, one of the segments analyzed in the report, is projected to record a 7% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Instruments segment is readjusted to a revised 4.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $707 Million, While China is Forecast to Grow at 9.7% CAGR

The Multiplex Assays market in the U.S. is estimated at US$707 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$870 Million by the year 2027 trailing a CAGR of 9.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

Software & Services Segment to Record 6.3% CAGR

In the global Software & Services segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$294.5 Million in the year 2020 will reach a projected size of US$435.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$543.3 Million by the year 2027, while Latin America will expand at a 7.5% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Coporation
  • Illumina, Inc.
  • Luminex Corporation
  • Merck KgaA
  • Meso Scale Diagnostics, LLC.
  • Olink
  • Qiagen NV
  • Quanterix Corporation
  • Randox Laboratories Ltd.
  • Seegene, Inc.
  • Thermo Fisher Scientific, Inc.
Table of Contents
Product Code: MCP13507

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Protein Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Nucleic Acid Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Cell-based Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Hospitals & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 31: USA Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 34: USA Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 40: Canada Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 46: Canada Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 49: Japan Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 52: Japan Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 55: Japan Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 58: China Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 61: China Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 64: China Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 67: Europe Current & Future Analysis for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 76: Europe Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 79: France Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 82: France Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 85: France Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: France 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 88: Germany Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Germany Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Germany 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 91: Germany Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 94: Germany Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Germany 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 97: Italy Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Italy Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Italy 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 100: Italy Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 103: Italy Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Italy 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 106: UK Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: UK Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: UK 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 109: UK Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 112: UK Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: UK 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 115: Spain Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Spain Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Spain 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 118: Spain Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Spain Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Spain 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 121: Spain Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Spain Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Spain 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 124: Russia Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Russia Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Russia 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 127: Russia Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Russia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Russia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 130: Russia Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Russia Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Russia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 133: Rest of Europe Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Europe Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of Europe 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 136: Rest of Europe Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 139: Rest of Europe Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of Europe Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Rest of Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 142: Asia-Pacific Current & Future Analysis for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 143: Asia-Pacific Historic Review for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Asia-Pacific 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 145: Asia-Pacific Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Asia-Pacific Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Asia-Pacific 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 148: Asia-Pacific Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 151: Asia-Pacific Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 154: Australia Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Australia Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Australia 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 157: Australia Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Australia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Australia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 160: Australia Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Australia Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Australia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 163: India Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: India Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: India 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 166: India Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: India Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: India 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 169: India Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: India Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: India 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 172: South Korea Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: South Korea Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: South Korea 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 175: South Korea Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: South Korea Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: South Korea 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 178: South Korea Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: South Korea Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: South Korea 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 181: Rest of Asia-Pacific Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Rest of Asia-Pacific Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 184: Rest of Asia-Pacific Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 187: Rest of Asia-Pacific Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 190: Latin America Current & Future Analysis for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 191: Latin America Historic Review for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Latin America 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 193: Latin America Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Latin America Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Latin America 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 196: Latin America Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 199: Latin America Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 202: Argentina Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Argentina Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Argentina 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 205: Argentina Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Argentina Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Argentina 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 208: Argentina Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Argentina Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Argentina 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 211: Brazil Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Brazil Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Brazil 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 214: Brazil Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Brazil Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Brazil 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 217: Brazil Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Brazil Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Brazil 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 220: Mexico Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Mexico Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 222: Mexico 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 223: Mexico Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Mexico Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 225: Mexico 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 226: Mexico Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Mexico Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 228: Mexico 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 229: Rest of Latin America Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Rest of Latin America Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 231: Rest of Latin America 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 232: Rest of Latin America Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Rest of Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 234: Rest of Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 235: Rest of Latin America Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Rest of Latin America Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 237: Rest of Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 238: Middle East Current & Future Analysis for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 239: Middle East Historic Review for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 240: Middle East 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 241: Middle East Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Middle East Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 243: Middle East 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 244: Middle East Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 246: Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 247: Middle East Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 249: Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 250: Iran Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Iran Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 252: Iran 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 253: Iran Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Iran Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 255: Iran 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 256: Iran Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Iran Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 258: Iran 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 259: Israel Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Israel Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 261: Israel 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 262: Israel Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Israel Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 264: Israel 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 265: Israel Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Israel Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 267: Israel 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 268: Saudi Arabia Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Saudi Arabia Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 270: Saudi Arabia 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 271: Saudi Arabia Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Saudi Arabia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 273: Saudi Arabia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 274: Saudi Arabia Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Saudi Arabia Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 276: Saudi Arabia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 277: UAE Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 278: UAE Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 279: UAE 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 280: UAE Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 281: UAE Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 282: UAE 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 283: UAE Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 284: UAE Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 285: UAE 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 286: Rest of Middle East Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Rest of Middle East Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 288: Rest of Middle East 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 289: Rest of Middle East Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Rest of Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 291: Rest of Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 292: Rest of Middle East Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Rest of Middle East Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 294: Rest of Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 295: Africa Current & Future Analysis for Multiplex Assays by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Africa Historic Review for Multiplex Assays by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 297: Africa 15-Year Perspective for Multiplex Assays by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 298: Africa Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Africa Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 300: Africa 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2012, 2020 & 2027
    • TABLE 301: Africa Current & Future Analysis for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Africa Historic Review for Multiplex Assays by End-Use - Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 303: Africa 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes and Reference Laboratories for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42